课题基金 / 基金详情

Clinical and Non-Clinical Evaluations of repeat administrations of the FAST PV and mGFR Technology

Clinical and Non-Clinical Evaluations of repeat administrations of the FAST PV and mGFR Technology
FAST PV 和 mGFR 技术重复给药的临床和非临床评估
批准号:
9148189
负责人:
Daniel Meier
金额:
$99.94万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-09-20 至 2018-07-31

项目摘要

项目成果

Daniel Meier的其他基金

相关文献

中文摘要
翻译
 描述(由申请方提供):Pharmaco Photonics(DBA FAST Biomedical)提出了一项IIB期项目,旨在确定FAST PV和mGFR技术在非临床和临床研究中重复给药的安全性和功能性。该SBIR项目的长期目标是在人体中测试FAST的荧光检测,并将该产品商业化,用于快速检测和定量急性肾损伤(阿基)、慢性肾病(CKD)和/或容量不稳定患者的肾小球滤过率(GFR)和血浆容量(PV)。阿基仍然是一个令人烦恼的临床问题,导致不可接受的高患者死亡率、CKD的发展和向终末期肾病的加速进展。FAST开发了FAST PV和mGFR技术,这是一种直接测量GFR和PV的简单采血技术。在CKD患者中,用于确定基线GFR和疾病进展和治疗反应的估计GFR(eGFR)方法已被证明是令人失望的。具有快速测量GFR(mGFR)的护理点能力将大大改善患者分层,管理和治疗评估。本试验预期作为当前用于评估肾功能的方法的辅助手段。本试验已在犬的生理和阿基条件下以及在人类CKD水平升高的情况下成功进行了测试。基于这一成功,FAST建议在重复给药非临床研究中测试FAST PV和mGFR Technology TM的重复给药(IIB期特定目标1)。基于非临床研究的成功,FAST提议在FDA-试验用器械豁免(IDE)初步人体试验(C)下,在人体中测试FAST PV和mGFR Technology TM的重复给药(IIB期特定目标2),以测定GFR和PV。将在接受体积(8)或蛋白质(8)挑战的16名健康志愿者中测定GFR和PV,以评价快速重复给药的试验安全性、有效性和可重复性,并量化肾储备。还将在另外八(8)名不同程度肾功能的志愿者中进行研究,并与碘酞酸盐清除率进行比较,两种方法均在一周后重复。这将允许在肾脏疾病中观察到的GFR范围内评价安全性和有效性,间隔一周重复给药,并与目前的标准进行比较。这种FAST PV和mGFR技术TM在阿基和CKD患者中具有重要的临床意义,尤其是在高风险患者中,这些患者需要进行密切监测以进行早期诊断、按严重程度分层和治疗反应。此外,这种用于快速测量GFR的新技术将首次允许在多种人类疾病动物模型中对肾功能进行早期动态评估;从而扩展了关于肾功能在早期疾病发作期间的作用的科学知识。最后,量化和动态跟踪PV的能力将大大提高 帮助重症监护医生治疗许多ICU患者。
英文摘要
 DESCRIPTION (provided by applicant): Pharmaco Photonics (DBA FAST Biomedical) proposes a PHASE IIB project to determine the safety and functionality of repeat administration of the FAST PV and mGFR Technology in both non-clinical and clinical studies. The long-term goal of this SBIR project is to test FAST's fluorescent based test in humans and commercializes this product for rapid detection and quantification of glomerular filtration rate (GFR) and plasma volume (PV) in patients with acute kidney injury (AKI) chronic kidney disease (CKD), and/or volume instability. AKI remains a vexing clinical problem resulting in unacceptably high patient mortality, development of CKD and enhanced progression to end stage renal disease. FAST has developed the FAST PV and mGFR Technology, a simple blood draw technique for direct measurement of GFR and PV. In CKD patients, the estimated GFR (eGFR) method for determining baseline GFR and following disease progression and response to therapy has proved to be a disappointment. Having a rapid point of care ability to measure GFR (mGFR) would greatly improve patient stratification, management and evaluation of therapies. The Test is intended as an adjunct to current methods utilized to assess renal function. This Test has been successfully tested under physiologic and AKI conditions in dogs and in increasing levels of CKD in humans. Based upon this success, FAST proposes to test the repeated administration of the FAST PV and mGFR Technology TM in repeat dose non-clinical studies (Phase IIB Specific Aim 1). Based on success of the non-clinical studies FAST proposes to test the repeated administration of the FAST PV and mGFR Technology TM in humans (Phase IIB Specific Aim 2) for determination of GFR and PV, under an FDA- Investigational Device Exemption (IDE) Pilot Human Trial (C). GFR and PV will be determined in sixteen (16) healthy volunteers receiving either a volume (8) or protein (8) challenge in order to evaluate the test's safety with rapid repeated doses, efficacy, and repeatability and quantify renal reserve. It will also be studied in an additional eight (8) volunteers of varying degrees of kidney function and compared to an iothalamate clearance with both repeated one week later. This will allow for the evaluation of safety and efficacy over the spectrum of GFRs seen in kidney disease, with repeat doses one week apart and compared to the present day standard. This FAST PV and mGFR Technology TM is of major clinical importance in AKI and CKD patients, especially in high risk patients where intense surveillance is necessary for early diagnosis, stratification by severity, and response to therapy. Furthermore, this new technology for rapid measurement of GFR will for the first time permit early dynamic assessment of kidney function in multiple animal models of human disease; thus expanding scientific knowledge regarding the role of kidney function during early disease onset. Finally, the ability to quantify and follow PV dynamically will greatly aid the critical care physician in many ICU patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical and Non-Clinical Evaluations of repeat administrations of the FAST PV and mGFR Technology
  • 批准号:
    9044217
  • 项目类别:
  • 资助金额:
    $99.97万
  • 财政年份:
    2011
  • 负责人:
    Daniel Meier
  • 依托单位:
Clinical Trial of the FAST Real-Time GFR System
  • 批准号:
    8399220
  • 项目类别:
  • 资助金额:
    $104.57万
  • 财政年份:
    2011
  • 负责人:
    Daniel Meier
  • 依托单位:
Clinical Trial of the FAST Real-Time GFR System
  • 批准号:
    8201449
  • 项目类别:
  • 资助金额:
    $17.26万
  • 财政年份:
    2011
  • 负责人:
    Daniel Meier
  • 依托单位: